$CMND

Clearmind Medicine Inc. (Nasdaq: CMND) agreed to acquire a 51% stake in Charging Robotics, a wireless charging solutions provider for automated parking and robotaxis, for $2.5M. The deal includes a $1.5M loan at 4% interest. Closing is expected by September 7, 2026, subject to conditions. Charging Robotics' technology offers up to 10 kW continuous charging with smart vehicle communication.

Clearmind Medicine (CMND) has started Phase IIa of its trial for CMND-100, a treatment for Alcohol Use Disorder, with six patients enrolled. The trial is evaluating safety, tolerability, and preliminary efficacy. The company reported positive data from earlier trial phases, supporting continued development. CMND-100 is Clearmind's lead investigational psychedelic-based therapeutic.

Clearmind Medicine (CMND) announced a U.S. patent application for a novel MDMA-PEA combination for PTSD, anxiety, and eating disorders, a milestone from its collaboration with NeuroThera Labs. The FDA's recent psychedelic drug guidance includes MDMA, providing regulatory context for Clearmind's program. CMND's stock closed at $1.74, up 0.87%, and is currently trading at the same price in the pre-market.

SciSparc (SPRC) and Clearmind (CMND) advanced their MDMA-PEA patent for PTSD treatment. The U.S. FDA issued psychedelic drug guidance, aiding their development. SPRC and CMND traded at $6.70 and $1.74 respectively, with slight premarket declines.

Clearmind Medicine (Nasdaq: CMND) said its independent DSMB approved advancing its FDA-regulated Phase I/II trial of CMND-100 for alcohol use disorder from Part A to Parts B and C. Part A met the primary safety endpoint in healthy participants. Part B will test 80 mg and 160 mg in AUD patients; Part C will test 160 mg in healthy participants.

Clearmind Medicine (CMND) reported intranasal MEAI permeation results, saying its mucoadhesive formulation achieved 97.35% cumulative permeation at 180 minutes versus 98.34% for a conventional MEAI solution. Using Franz diffusion cells and simulated nasal fluid, the company said permeation kinetics were preserved despite a slower early release. CMND is developing MEAI for AUD and metabolic indications.

Clearmind Medicine Inc. (Nasdaq: CMND) reported positive permeation results for its intranasal MEAI formulation. Using Franz diffusion cells, both the intranasal formulation and a conventional reference solution showed rapid permeation, reaching near-complete permeation by 180 minutes (97.35% vs 98.34%). The company says enhanced nasal retention does not impair transport and supports continued MEAI development for mental-health and weight management.

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

Clearmind Medicine Inc. (Nasdaq: CMND) reported early Phase I/IIa first-in-human trial updates for CMND-100, its non-hallucinogenic MEAI compound for alcohol use disorder, based on a June 10 webinar. Investigators from Yale and Johns Hopkins cited generally positive impressions, good volunteer recruitment, and an early safety profile with no meaningful adverse or cardiac concerns to date.

Clearmind Medicine Inc. (Nasdaq: CMND) said it submitted a formal response to a U.S. HHS Request for Information on MEAI for addiction treatment under the Great American Recovery Initiative. The company highlighted its MEAI-based candidate CMND-100 for alcohol use disorder, citing AUD affects about 10% of the U.S. population and only 1 in 10 receives treatment.